Compare DNN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | IDYA |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.9B |
| IPO Year | 1998 | 2019 |
| Metric | DNN | IDYA |
|---|---|---|
| Price | $3.18 | $29.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $6.50 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 21.5M | 780.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $403.36 | N/A |
| Revenue Next Year | N/A | $201.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $1.51 | $18.26 |
| 52 Week High | $4.43 | $39.28 |
| Indicator | DNN | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 49.97 |
| Support Level | $2.56 | $29.51 |
| Resistance Level | $3.36 | $31.07 |
| Average True Range (ATR) | 0.19 | 1.12 |
| MACD | -0.07 | 0.22 |
| Stochastic Oscillator | 9.55 | 84.69 |
Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.